Review
Chemistry, Medicinal
Kaidireyahan Wumaier, Wenqian Li, Jiuwei Cui
Summary: Venous thromboembolism (VTE) in cancer patients is associated with increased morbidity and mortality, decreased quality of life, and higher economic burden. Low molecular weight heparin (LMWHs) has been the standard treatment for cancer-associated VTE, but the introduction of new oral anticoagulants (NOACs) offers another option for some cancer patients with thrombosis. A more comprehensive understanding of drug properties, efficacy and safety, and economic analysis is needed to choose the most appropriate treatment.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2022)
Article
Medicine, General & Internal
Irit Ayalon-Dangur, Yakov Vega, Miriam Rozi Israel, Alon Grossman, Galia Spectre, Tzippy Shochat, Leonard Leibovici, Anat Gafter-Gvili
Summary: A retrospective cohort study found that treating elderly patients with VTE using DOACs resulted in a lower rate of the composite outcome compared to VKA group.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Clinical Neurology
Shadi Yaghi, Ian J. Saldanha, Chelsea Misquith, Bashar Zaidat, Asghar Shah, Kareem Joudi, Bianca Persaud, Feras Abdul Khalek, Liqi Shu, Adam de Havenon, Eva A. Mistry, Ekaterina Bakradze, Eric D. Goldstein, John Reagan, Aikaterini Theodorou, Lina Palaiodimou, Karen Furie, Thalia S. Field, Georgios Tsivgoulis, Brian Mac Grory
Summary: This systematic review and meta-analysis suggest that DOACs and warfarin may have comparable efficacy and safety in patients with cerebral venous thrombosis. However, due to the limitations of the included studies, caution should be exercised in interpreting these findings until confirmation is obtained from ongoing randomized controlled trials and large, prospective, observational studies.
Article
Clinical Neurology
Anita van de Munckhof, Mayte Sanchez van Kammen, Katarzyna Krzywicka, Sanjith Aaron, Diana Aguiar de Sousa, Florina Antochi, Antonio Arauz, Miguel A. Barboza, Adriana B. Conforto, Francesco Dentali, Daniel Galdames Contreras, Xunming Ji, Katarina Jood, Mirjam R. Heldner, Maria Hernandez-Perez, Wayneho Kam, Timothy J. Kleinig, Espen S. Kristoffersen, Ronen R. Leker, Robin Lemmens, Sven Poli, Niluefer Yesilot, Mohammad Wasay, Teddy Y. Wu, Marcel Arnold, Lia Lucas-Neto, Saskia Middeldorp, Jukka Putaala, Turgut Tatlisumak, Jose M. Ferro, Jonathan M. Coutinho, DOAC-CVT Study Grp
Summary: This study aims to compare the efficacy and safety of DOACs and VKAs for the prevention of recurrent venous thrombotic events in patients with CVT. DOAC-CVT will provide real-world data on the comparative effectiveness of DOACs versus VKAs in treating CVT.
FRONTIERS IN NEUROLOGY
(2023)
Article
Hematology
Sang-A Kim, Ju Hyun Lee, Ji Yun Lee, Hun-Gyu Hwang, Yang-Ki Kim, Ho-Young Yhim, Junshik Hong, Jeong-Ok Lee, Soo-Mee Bang
Summary: This study found that DOACs have become the most prescribed anticoagulant in Korea after five years, but bleeding complications occurred more frequently in CT patients, especially in those treated with DOACs.
THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Cardiac & Cardiovascular Systems
Joris J. Komen, Anton Pottegard, Aukje K. Mantel-Teeuwisse, Tomas Forslund, Paul Hjemdahl, Bjorn Wettermark, Jesper Hallas, Morten Olesen, Marion Bennie, Tanja Mueller, Raymond Carragher, Oystein Karlstad, Lars J. Kjerpeseth, Olaf H. Klungel
Summary: Observational data suggests that NOAC treatment may have a positive net clinical benefit compared with no treatment or VKA treatment in low stroke risk patients.
EUROPEAN HEART JOURNAL
(2022)
Article
Medicine, General & Internal
Anna Szpotowicz, Iwona Gorczyca, Olga Jelonek, Beata Uzieblo-Zyczkowska, Malgorzata Maciorowska, Maciej Wojcik, Robert Blaszczyk, Agnieszka Kaplon-Cieslicka, Monika Gawalko, Monika Budnik, Tomasz Tokarek, Renata Rajtar-Salwa, Jacek Bil, Michal Wojewodzki, Janusz Bednarski, Elwira Bakula-Ostalska, Anna Tomaszuk-Kazberuk, Anna Szyszkowska, Marcin Welnicki, Artur Mamcarz, Malgorzata Krzciuk, Beata Wozakowska-Kaplon
Summary: Most AF patients at high risk of thromboembolic complications received OACs, but certain medical conditions may result in the lack of OAC therapy in these patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Paul Lewis, Jennifer L. Tharp
Summary: Therapeutic failure with DOACs seems to be common in COVID-19 patients, and further research is needed to determine if there is an underlying cause for this association.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
(2021)
Review
Hematology
Allen Li, Ming Chan Zhang, Pei Li, Ali Eshaghpour, Katherine Li, Marc Carrier, Philip Wells, Mark Andrew Crowther
Summary: This study compared the efficacy and safety of direct oral anticoagulants (DOACs) with low-molecular-weight heparins (LMWHs), vitamin-k antagonists (VKAs), or no anticoagulation in patients with splanchnic vein thrombosis (SVT). The results showed that DOACs were more effective than VKAs in non-cirrhotic patients and had a reduced risk of major bleeding compared to observation, LMWHs, and VKAs. However, no difference in major bleeding was found between DOACs and other treatment options in cirrhotic patients.
THROMBOSIS RESEARCH
(2023)
Review
Medicine, General & Internal
Antonio Gabriele Franchina, Matteo Rocchetti, Elena Sala, Alessandra Laricchia, Alessandro Minardi, Andrea Spangaro, Marco Guazzi, Stefano Lucreziotti, Alberto Cereda
Summary: There is a relationship between malignancy and impaired hemostasis, making it challenging to balance clotting and bleeding risks. Half of cancer patients with atrial fibrillation (AF) do not receive any oral anticoagulation (OAC). Comparing vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) in AF cancer patients, it was found that DOACs have similar or lower rates of efficacy and safety outcomes compared to VKAs. DOACs may be a preferable option for thromboembolic prophylaxis in cancer patients with non-valvular AF.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
T. Quintanar, C. Font, E. Gallardo, R. Barba, B. Obispo, C. Diaz-Pedroche
Summary: The study found that up to 20% of cancer patients will develop some manifestation of venous thromboembolic disease (VTD) during their clinical course, which greatly impacts morbidity, mortality, quality of life and pharmaceutical expenditure. It is important to carefully review all the risk factors involved in making the decision to establish secondary thromboprophylaxis as an indefinite treatment in these patients.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2021)
Article
Hematology
Jesse Popov, Suellen Coelho, Marc Carrier, Catherine Sperlich, Susan Solymoss, Nathalie Routhier, Sudeep Shivakumar, Wusiman Aibibula, Susan R. Kahn, Vicky Tagalakis
Summary: This study explored the feasibility of extended prophylactic-dose low molecular weight heparin (LMWH) treatment for patients with cancer-associated thrombosis (CAT) who had completed at least 3 months of therapeutic-dose LMWH. The results suggest that extended reduced-dose anticoagulation may be effective in preventing recurrent deep vein thrombosis or pulmonary embolism in CAT patients.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Hematology
Jerome J. Federspiel, Lauren E. Wein, Ryan Duggal, Evan R. Myers, Kimberly A. Boggess, Andra H. James
Summary: The adoption of different guidelines has notable implications for clinical practice and the rate of VTE following cesarean delivery may vary accordingly.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
Review
Medicine, Research & Experimental
Stefano Ballestri, Elisa Romagnoli, Dimitriy Arioli, Valeria Coluccio, Alessandra Marrazzo, Afroditi Athanasiou, Maria Di Girolamo, Cinzia Cappi, Marco Marietta, Mariano Capitelli
Summary: This article systematically evaluates the risk of bleeding complications of direct oral anticoagulants (DOACs) compared to vitamin K antagonists (VKAs) in patients with atrial fibrillation and venous thromboembolism. It also discusses the management of bleeding complications and the possibility of resuming anticoagulation for special patient populations. Recommendations for choosing the optimal DOAC to minimize adverse events according to individual patient characteristics and bleeding risk are provided.
ADVANCES IN THERAPY
(2023)
Article
Health Care Sciences & Services
Francesco De Stefano, Alberto Benassi, Alberto Maria Cappelletti, Francesco Donatelli, Damiano Regazzoli, Salvatore Tolaro, Francesca Perego, Angelo Silverio, Alessandra Scatteia, Pasquale Guarini, Santo Dellegrottaglie, Simona Mariani, Elpidio Pezzella, Gennaro Galasso, Francesco Caiazza
Summary: This study evaluated the real-world use of oral anticoagulant therapy in patients aged ≥80 years and investigated patient tolerance and satisfaction with the therapy. The majority of patients were treated with non-vitamin K antagonist oral anticoagulants (NOACs), with a small proportion receiving vitamin K antagonists (VKAs). Patients treated with NOACs reported a higher level of satisfaction and improved quality of life.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Matteo Casale, Michele Correale, Giulia Laterra, Vittoria Vaccaro, Claudia Morabito, Pasquale Crea, Salvatore Santo Signorelli, Niki Katsiki, Francesco Luzza, Cesare de Gregorio, Giuseppe Dattilo
Summary: Patients with heart failure with reduced ejection fraction (HFrEF) can benefit significantly from treatment with sacubitril/valsartan, especially those with an implantable cardioverter defibrillator (ICD). Clinical improvement is evident within the first 6 months of treatment, while reverse remodeling takes more time to occur.
CLINICAL DRUG INVESTIGATION
(2021)
Review
Cardiac & Cardiovascular Systems
Michele Correale, Renata Petroni, Stefano Coiro, Elena-Laura Antohi, Francesco Monitillo, Marta Leone, Marco Triggiani, Shiro Ishihara, Hans-Dirk Dungen, Chaudhry M. S. Sarwar, Maurizio Memo, Hani N. Sabbah, Marco Metra, Javed Butler, Savina Nodari
Summary: Novel antidiabetic oral medications (SGLT2i) have shown significant beneficial effects in treating high-risk HF populations, reducing mortality and HF hospitalization rates. These drugs may become an important component of chronic heart failure treatment.
HEART FAILURE REVIEWS
(2022)
Review
Medicine, General & Internal
Alberto Palazzuoli, Michele Correale, Massimo Iacoviello, Edoardo Gronda
Summary: Left ventricular ejection fraction (LVEF) is widely accepted as a measure of cardiac systolic function, but it may not accurately reflect the contractile performance of the left ventricle. In patients with heart failure with preserved ejection fraction (HFpEF), LVEF does not reflect effective systolic function and does not consider longitudinal and torsional contraction. Alternative measurements are needed to better reflect the true hemodynamic status.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Medicine, General & Internal
Lorenzo Pistelli, Francesca Parisi, Michele Correale, Federica Cocuzza, Francesca Campanella, Tommaso de Ferrari, Pasquale Crea, Rosalba De Sarro, Olga La Cognata, Simona Ceratti, Tonino Recupero, Gaetano Ruocco, Alberto Palazzuoli, Egidio Imbalzano, Giuseppe Dattilo
Summary: Heart failure is a complex condition affecting millions of people worldwide, with significant impacts on morbidity, mortality, and healthcare costs. Over the past 50 years, numerous therapeutic options have been developed based on a better understanding of the underlying pathophysiology. The recent inclusion of sodium-glucose cotransporter inhibitors as first-line therapy for heart failure with reduced ejection fraction in the European Society of Cardiology guidelines highlights the potential benefits of these drugs in reducing hospitalizations and mortality.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, General & Internal
Michele Correale, Michele Magnesa, Pietro Mazzeo, Martino Fortunato, Lucia Tricarico, Alessandra Leopizzi, Adriana Mallardi, Raffaele Mennella, Francesca Croella, Massimo Iacoviello, Matteo Di Biase, Natale Daniele Brunetti
Summary: This study investigated the improvement and reverse remodeling of left ventricular and left atrial in patients with heart failure after therapy with Sacubitril/Valsartan. Results showed that after 6 months of S/V treatment, the functional reverse remodeling of the left atrium improved. The changes in left ventricular volumes and left atrial strain parameters were significantly correlated with the reverse remodeling of the left atrium.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Medicine, General & Internal
Michele Correale, Francesco Fioretti, Lucia Tricarico, Francesca Croella, Natale Daniele Brunetti, Riccardo M. Inciardi, Anna Vittoria Mattioli, Savina Nodari
Summary: In heart failure with reduced ejection fraction, edema and congestion are common symptoms related to reduced cardiac function. Edema and congestion are further worsened by chronic kidney failure and pulmonary abnormalities. Sodium/water retention is an important sign of heart failure progression, often preceding clinical symptoms and associated with reduced quality of life and increased mortality risk. This review focuses on the role of congestion biomarkers in diagnosing, predicting prognosis, and guiding therapeutic approaches in HFrEF patients, and also explores the impact of new HF drugs on congestion biomarkers.
JOURNAL OF CLINICAL MEDICINE
(2023)
Editorial Material
Medicine, General & Internal
Michele Correale, Lucia Tricarico, Massimo Iacoviello, Natale Daniele Brunetti
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Medicine, General & Internal
Giulia Laterra, Giuseppe Dattilo, Michele Correale, Natale Daniele Brunetti, Claudia Artale, Giorgio Sacchetta, Lorenzo Pistelli, Marco Borgi, Francesca Campanella, Federica Cocuzza, Maria Claudia Lo Nigro, Marco Contarini
Summary: Atrial fibrillation (AF) is the most common cardiac arrhythmia in adults, and the left atrial appendage (LAA) is the most likely source of thrombus formation in patients with non-valvular AF. Left atrial appendage closure (LAAC) is an effective alternative to NOAC in patients with non-valvular AF. Intraprocedural imaging using transesophageal echocardiography (TEE) or intracardiac echocardiography (ICE) is recommended to guide LAAC, but ICE imaging techniques are not yet simplified and standardized. The use of ICE via the esophageal route (ICE-TEE) may be a good alternative imaging technique for LAAC procedure without general anesthesia.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Davide Diomede, Erica Terazzi, Nicolangelo Diomede, Gianmarco Alcidi, Rosanna Pugliese, Sara Ioannoni, Matteo Romano, Michele Granatiero, Vito Di Terlizzi, Michele Correale, Matteo Di Biase, Natale Daniele Brunetti, Massimo Iacoviello
Summary: The study aimed to evaluate the role of left atrial strain parameters in predicting worsening chronic heart failure. In patients with heart failure, left atrial volume and contraction assessed by 2D-STE were found to be associated with heart failure worsening. The measurement of left atrial volume in combination with Doppler measures of diastolic function provides a more accurate prediction of heart failure events.
ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES
(2023)
Review
Biochemistry & Molecular Biology
Gianpaolo Palmieri, Maria Francesca D'Ambrosio, Michele Correale, Natale Daniele Brunetti, Rosa Santacroce, Massimo Iacoviello, Maurizio Margaglione
Summary: The relevance of genetics in cardiovascular diseases, especially in the context of cardiomyopathies, has expanded over the last decades. Genetic variants hold potential as therapeutic targets, but a comprehensive evaluation of the affected patients' family lineage is necessary. Collaboration between cardiologists specializing in cardiomyopathies and HF, and geneticists, is crucial in improving individual and family health outcomes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, General & Internal
Giuseppe Dattilo, Giulia Laterra, Roberto Licordari, Francesca Parisi, Lorenzo Pistelli, Luigi Colarusso, Luca Zappia, Vittoria Vaccaro, Elisabetta Demurtas, Marta Allegra, Pasquale Crea, Gianluca Di Bella, Salvatore Santo Signorelli, Nadia Aspromonte, Egidio Imbalzano, Michele Correale
Summary: This study evaluated the effects of Sacubitril/Valsartan treatment in patients with HFrEF for a period of 5 years. The results showed that the treatment not only improved patient outcomes after 1 year, but continued to show significant improvements at 5 years, with profound clinical implications.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, General & Internal
Erika Tabella, Michele Correale, Gianmarco Alcidi, Rosanna Pugliese, Sara Ioannoni, Matteo Romano, Gianpaolo Palmieri, Matteo Di Biase, Natale Daniele Brunetti, Massimo Iacoviello
Summary: This study evaluates the feasibility and interaction of SGLT2 inhibitors (SGLT2i) with other drug classes in patients with chronic heart failure. The findings demonstrate that SGLT2i are primarily prescribed to HFrEF patients in real-world practice and show significant therapeutic effects in a short-term follow-up.
CLINICS AND PRACTICE
(2023)
Review
Geriatrics & Gerontology
Michele Correale, Lucia Tricarico, Martino Fortunato, Giuseppe Dattilo, Massimo Iacoviello, Natale Daniele Brunetti
Summary: The recent COVID-19 pandemic has sparked increased research interest in the relationship between thromboembolism and Sars-Cov-2 infection, focusing on endothelial dysfunction, platelet activation, coagulation, and inflammatory immune responses in patients. However, previous studies on the link between microorganisms or infections and thrombotic events have shown fluctuating interest. This study aims to summarize previous evidence on this topic and compare it with current data on SARS-COV2 infections.
AGING CLINICAL AND EXPERIMENTAL RESEARCH
(2021)
Article
Cardiac & Cardiovascular Systems
Michele Correale, Ilenia Monaco, Armando Ferraretti, Lucia Tricarico, Giuseppina Padovano, Ennio Sascia Formica, Valeria Tozzi, Davide Grazioli, Matteo Di Biase, Natale Daniele Brunetti
IJC HEART & VASCULATURE
(2019)
Article
Cardiac & Cardiovascular Systems
Raffaella Antonione, Gianfranco Sinagra, Matteo Moroni, Michele Correale, Dario Redaelli, Domenico Scrutinio, Eugenia Malinverni, Savina Nodari, Raffaele Calabro, Italo Penco, Giuseppe Mercuro
GIORNALE ITALIANO DI CARDIOLOGIA
(2019)